Citations

Clear

133 citation(s) found for "Church, An".

Abstract 818: Fighting prostate cancer with a multimedia approach
Gordon, Vinessa, Odedina, Folakemi T., Ashing, Kimling Tam, Merriweather, Arnold, Dronca, Roxana , Odedina, Abimbola, Hill, Anthony B., Yahaya, Ayinde, Agboola, Emmanuel, Ashing, Kimlin , Ngufor, Che , Rotimi, Solomon O. , Kaninjing, Ernest , McCall, John , Hill, Anthony

Mayo Clinic

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 818-818

10.1158/1538-7445.am2024-818 Get It

Abstract Introduction: Black men have the highest prostate cancer (CaP) mortality rates. The reason for this disparity is multifaceted, including the barriers that they face at the individual, provider, and health system levels. To address these challenges the iCCaRE for Black Men Consortium uses a multi-level approach to disseminating CaP information. This approach is rooted in research which shows that Black men prefer to receive information through multi-media channels tailored to their needs. In addition, studies have reported that CaP survivors were viewed as credible sources of information. This presentation reports on how iCCaRE Consortium is bridging the digital divide in minoritized communities to disseminate CaP information in a way that is meaningful to the community. Methodology: iCCaRE uses a multimedia method to reach Black men. This includes twitter post, Facebook, YouTube, ecancer and community lunch and learns. In addition to social media, we have partnered with LitTV Network, a locally owned digital TV platform, on which we have iCCaRE TV. On Lit TV network we have the ability to reach 11,000 homes in our catchment area. Furthermore, the consortium has produced informational flyers that are disseminated at outreach events and at the American Legion Post 197. On the twitter page the consortium post: (1) 2 scientific publications per day authored by members of the consortium, (2) 2 weekly “Did You Know” facts about prostate cancer with sources attached, (3) 2 weekly url post sharing a link to a video from the iCCaRE consortium YouTube page and (4) clips of CaP survivors sharing their experiences. On the YouTube page we currently have: videos series of a CaP survivor who is also a physician scientist, interview series with MPIs and members of the consortium, CaP survivor series including a barbershop interview with a survivor. Results: The iCCaRE Consortium multimedia efforts have a global reach, in less than a year we have gained 102 twitter followers. On average the twitter page receives 8,700 impressions during the CaP awareness month in September the twitter page garnered over 14,000 impressions. Our videos on the ecancer platform have a combined global view of 341 representing countries such as the United States, Nigeria, Cameroon, United Kingdom, Macedonia, and Mexico. The American Legion Post 197 in North Jacksonville has served a cumulative of 229 people through outreach and educational event called lunch and learns. Our YouTube channel has had almost 100 views in its first month of being active. Conclusion: Using a multi-level approach to reduce the burden of CaP for Black men is vitally important; without such efforts the disparate thread in mortality will continue to persist. Meeting Black men through the mediums they use for gathering health information removes barriers, increases access and will aid in the fight against CaP for Black Men. Citation Format: Vinessa Gordon, Folakemi Odedina, Kimling Tam Ashing, Arnold Merriweather, Roxana Dronca, Che Ngufor, Solomon Rotimi, Ernest Kaninjing, Abimbola Odedina, John McCall, Anthony Hill, Ayinde Yahaya, Emmanuel Agboola. Fighting prostate cancer with a multimedia approach [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 818.
Discordance in Recommendation Between Next-Generation Sequencing Test Reports and Molecular Tumor Boards in India
Mathew, Aju , Davis, Sissmol , Boby, Jeffrey Mathew , I, Anu R , Suryavanshi, Moushumi , Dawood, Shaheenah , Panda, Pankaj Kumar , Nag, Shona, Das, Arunangshu, Rohatgi, Nitesh, Shah, Riyaz , Thampy, Cherian, Mukherji, Deborah , Shilpakar, Ramila , Mullapally, Sujith Kumar, Popat, Sanjay , Parikh, Aparna Raj , Yadav, Siddhartha , Mehta, Prashant , Mukherji, Deborah , Shilpakar, Ramila , Mullapally, Sujith Kumar , Sirohi, Bhawna , Dawood, Shaheenah , Popat, Sanjay , Parikh, Aparna R. , Yadav, Siddhartha , Singh, Randeep K. , Sirohi, Bhawna

Mayo Clinic

JCO Global Oncology | March 14, 2024 | Volume: No volume available | Issue: 10 | Pages: No page available

10.1200/go.23.00330 | PMID 38484196 Get It

PURPOSE Accurate understanding of the genomic and transcriptomic data provided by next-generation sequencing (NGS) is essential for the effective utilization of precision oncology. Molecular tumor boards (MTBs) aim to translate the complex data in NGS reports into effective clinical interventions. Often, MTB treatment recommendations differ from those in the NGS reports. In this study, we analyze the discordance between these recommendations and the rationales behind the discordances, in a non–high-income setting, with international input to evaluate the necessity of MTB in clinical practice. METHODS We collated data from MTB that were virtually hosted in Chennai, India. We included patients with malignancies who had NGS reports on solid tissue or liquid biopsies, and excluded those with incomplete data. MTB forms and NGS reports of each clinical case were analyzed and evaluated for recommendation concordance. Concordance was defined as an agreement between the first recommendation in the MTB forms and the therapeutic recommendations suggested in the NGS report. Discordance was the absence of the said agreement. The rationales for discordance were identified and documented. RESULTS Seventy MTB reports were analyzed with 49 cases meeting the inclusion criteria. The recommendation discordance was 49% (24 of 49). Discordant recommendations were mainly due to low level of evidence for the drug (75% of cases). CONCLUSION The discordance between MTB and NGS vendor recommendations highlights the clinical utility of MTB. The educational experiences provided by this initiative are an example of how virtual academic collaborations can enhance patient care and provider education across geographic borders.
Need for a Cardiogenic Shock Team Collaborative—Promoting a Team‐Based Model of Care to Improve Outcomes and Identify Best Practices
Senman, Balimkiz , Jentzer, Jacob C. , Barnett, Christopher F. , Bartos, Jason A. , Berg, David D. , Chih, Sharon , Drakos, Stavros G. , Dudzinski, David M. , Elliott, Andrea , Horowitz, James M. , Miller, P. Elliott , Tehrani, Behnam , Vallabhajosyula, Saraschandra , Katz, Jason N. , Horowitz, James M , Miller, P Elliott , Sinha, Shashank S , Yuriditsky, Eugene , Vallabhajosyula, Saraschandra , Katz, Jason N , Jentzer, Jacob C , Berg, David , Gage, Ann

Mayo Clinic

Journal of the American Heart Association | March 8, 2024 | Volume: 13 | Issue: 6 | Pages: No page available

10.1161/jaha.123.031979 | PMID 38456417 Get It

Cardiogenic shock continues to carry a high mortality rate despite contemporary care, with no breakthrough therapies shown to improve survival over the past few decades. It is a time‐sensitive condition that commonly results in cardiovascular complications and multisystem organ failure, necessitating multidisciplinary expertise. Managing patients with cardiogenic shock remains challenging even in well‐resourced settings, and an important subgroup of patients may require cardiac replacement therapy. As a result, the idea of leveraging the collective cognitive and procedural proficiencies of multiple providers in a collaborative, team‐based approach to care (the “shock team”) has been advocated by professional societies and implemented at select high‐volume clinical centers. A slowly maturing evidence base has suggested that cardiogenic shock teams may improve patient outcomes. Although several registries exist that are beginning to inform care, particularly around therapeutic strategies of pharmacologic and mechanical circulatory support, none of these are currently focused on the shock team approach, multispecialty partnership, education, or process improvement. We propose the creation of a Cardiogenic Shock Team Collaborative—akin to the successful Pulmonary Embolism Response Team Consortium—with a goal to promote sharing of care protocols, education of stakeholders, and discovery of how process and performance may influence patient outcomes, quality, resource consumption, and costs of care.
Projected Colorectal Cancer Incidence and Mortality Based on Observed Adherence to Colonoscopy and Sequential Stool-Based Screening
Meester, Reinier G.S. , Lansdorp‐Vogelaar, Iris , Winawer, Sidney J., Church, Timothy R. , Allen, John I., Feld, Andrew D., Mills, Glenn, Jordan, Paul, Corley, Douglas A. , Doubeni, Chyke A. , Fleisher, Martin, Hahn, Anne I , Church, Timothy R , Doubeni, Chyke A. , Lobaugh, Stephanie M , O’Brien, Michael J. , Zauber, Ann Graham

Mayo Clinic

American Journal of Gastroenterology | February 6, 2024 | Volume: 119 | Issue: 7 | Pages: 1392-1401

10.14309/ajg.0000000000002693 | PMID 38318949 Get It

INTRODUCTION: Modeling supporting recommendations for colonoscopy and stool-based colorectal cancer (CRC) screening tests assumes 100% sequential participant adherence. The impact of observed adherence on the long-term effectiveness of screening is unknown. We evaluated the effectiveness of a program of screening colonoscopy every 10 years vs annual high-sensitivity guaiac-based fecal occult blood testing (HSgFOBT) using observed sequential adherence data. METHODS: The MIcrosimulation SCreening ANalysis (MISCAN) model used observed sequential screening adherence, HSgFOBT positivity, and diagnostic colonoscopy adherence in HSgFOBT-positive individuals from the National Colonoscopy Study (single-screening colonoscopy vs ≥4 HSgFOBT sequential rounds). We compared CRC incidence and mortality over 15 years with no screening or 10 yearly screening colonoscopy vs annual HSgFOBT with 100% and differential observed adherence from the trial. RESULTS: Without screening, simulated incidence and mortality over 15 years were 20.9 (95% probability interval 15.8–26.9) and 6.9 (5.0–9.2) per 1,000 participants, respectively. In the case of 100% adherence, only screening colonoscopy was predicted to result in lower incidence; however, both tests lowered simulated mortality to a similar level (2.1 [1.6–2.9] for screening colonoscopy and 2.5 [1.8–3.4] for HSgFOBT). Observed adherence for screening colonoscopy (83.6%) was higher than observed sequential HSgFOBT adherence (73.1% first round; 49.1% by round 4), resulting in lower simulated incidence and mortality for screening colonoscopy (14.4 [10.8–18.5] and 2.9 [2.1–3.9], respectively) than HSgFOBT (20.8 [15.8–28.1] and 3.9 [2.9–5.4], respectively), despite a 91% adherence to diagnostic colonoscopy with FOBT positivity. The relative risk of CRC mortality for screening colonoscopy vs HSgFOBT was 0.75 (95% probability interval 0.68–0.80). Findings were similar in sensitivity analyses with alternative assumptions for repeat colonoscopy, test performance, risk, age, and projection horizon. DISCUSSION: Where sequential adherence to stool-based screening is suboptimal and colonoscopy is accessible and acceptable—as observed in the National Colonoscopy Study—offering screening colonoscopy can increase screening effectiveness.
Blenderized tube feedings: Practice recommendations from the American Society for Parenteral and Enteral Nutrition
Epp, Lisa , Blackmer, Allison B. , Church, April , Ford, Ivy, Grenda, Brandee, Larimer, Cara , Lewis‐Ayalloore, Joanna, Malone, Ainsley , Pataki, L, Rempel, Gina , Washington, Vita, Blackmer, Allison , Malone, Ainsley , Pataki, Linda

Mayo Clinic

Nutrition in Clinical Practice | October 4, 2023 | Volume: 38 | Issue: 6 | Pages: 1190-1219

10.1002/ncp.11055 | PMID 37787762 Get It

Abstract Prior to the 1970s, blending food and liquids and putting them through an enteral access device (EAD) was the most common form of enteral nutrition (EN). However, in the 1970s, blenderized tube feedings (BTFs) became less popular due to the emergence of modern commercial enteral formulas (CEFs). Recently, a cultural shift toward consuming a natural diet, consisting of whole foods, has led to a resurgence in the use of BTF. The increasing use of BTF in a variety of patient care settings identifies a need for practice recommendations that provide guidance for nutrition professionals and patients. Members of the American Society for Parental and Enteral Nutrition (ASPEN) Enteral Nutrition Committee identified salient clinical questions concerning BTF, conducted a comprehensive literature search, and subsequently developed practice recommendations pertaining to the use of BTF. This paper was approved by the ASPEN 2022–2023 Board of Directors.
Cutaneous Atypical Fibroxanthoma With Osteoclast-Like Giant Cell: A Rare but Diagnostic Pitfall
Shaker, Nada , Phelps, Robert , Niedt, George, Patel, Ankush , Wu, Douglas, Prieto, Víctor G. , Church, Ann, Shaker, Nada , Patel, Ankush U , Aung, Phyu P , Pradhan, Dinesh

Mayo Clinic

The American Journal of Dermatopathology | September 14, 2023 | Volume: 45 | Issue: 10 | Pages: 704-707

10.1097/dad.0000000000002508 | PMID 37708369 Get It

Background: Atypical fibroxanthoma (AFX) is a dermal-based, low-grade neoplasm with no specific lineage of differentiation. The occurrence of AFX with osteoclast-like giant cells is exceptionally rare. Less than 20 cases have been reported in the literature. Case Presentation: A 77-year-old man with a medical history of multiple basal and squamous cell carcinomas of the skin, presented with a progressively growing erythematous nodule on the sun-damaged right central parietal scalp. A shave biopsy showed a dermal spindle cell proliferation accompanied by numerous osteoclast-like multinucleated giant cells and predominant atypical mitotic figures. The immunohistochemical staining showed a diffuse positive staining for CD68 and SMA, patchy staining for CD10, and negative staining for SOX-10, pan-cytokeratin, CK5/6, S100, CD34, and desmin. The tumor was completely excised with negative margins. A subsequent follow-up over a period of 13 months showed no recurrence. Conclusion: Distinguishing AFX with osteoclast-like giant cells from both malignant and benign skin lesions with osteoclast-like giant cells is crucial. Although AFX tumors display worrisome malignant histologic features, most cases have a favorable prognosis with a local recurrence rate below 5% and exceedingly rare metastasis.
Recommendations for Standardizing MRI-based Evaluation of Perianal Fistulizing Disease Activity in Pediatric Crohn’s Disease Clinical Trials
Crowley, Eileen , Ma, Christopher , Guizzetti, Leonard, Lewindon, Peter , Gee, Michael S. , Hyams, Jeffrey S. , Rosen, Michael J. , Allmen, Daniel von, Overstraeten, Anthony de Buck van , Shackelton, Lisa M. , Rémillard, Julie, Schleicher, Lauren S., Rimola, Jordi , Taylor, Stuart A. , Church, Peter , Feagan, Brian G. , Jairath, Vipul , Jairath, Vipul , Jairath, Vipul , Hyams, Jeffrey S , Shackelton, Lisa M , Rimola, Jordi , Ma, C , Jairath, V , Jairath, V , Jairath, Vipul , Zou, Guangyong , Gee, Michael Stanley , Dillman, Jonathan R , Fletcher, Joel G. , Griffiths, Anne Marie , Greer, Mary‐Louise C.

Mayo Clinic

Inflammatory Bowel Diseases | July 31, 2023 | Volume: 30 | Issue: 3 | Pages: 357-369

10.1093/ibd/izad134 | PMID 37524088 Get It

Abstract Background Perianal fistulas and abscesses occur commonly as complications of pediatric Crohn’s disease (CD). A validated imaging assessment tool for quantification of perianal disease severity and activity is needed to evaluate treatment response. We aimed to identify magnetic resonance imaging (MRI)-based measures of perianal fistulizing disease activity and study design features appropriate for pediatric patients. Methods Seventy-nine statements relevant to MRI-based assessment of pediatric perianal fistulizing CD activity and clinical trial design were generated from literature review and expert opinion. Statement appropriateness was rated by a panel (N = 15) of gastroenterologists, radiologists, and surgeons using modified RAND/University of California Los Angeles appropriateness methodology. Results The modified Van Assche Index (mVAI) and the Magnetic Resonance Novel Index for Fistula Imaging in CD (MAGNIFI-CD) were considered appropriate instruments for use in pediatric perianal fistulizing disease clinical trials. Although there was concern regarding the use of intravascular contrast material in pediatric patients, its use in clinical trials was considered appropriate. A clinically evident fistula tract and radiologic disease defined as at least 1 fistula or abscess on pelvic MRI were considered appropriate trial inclusion criteria. A coprimary clinical and radiologic end point and inclusion of a patient-reported outcome were also considered appropriate. Conclusion Outcomes of treatment of perianal fistulizing disease in children must include MRI. Existing multi-item measures, specifically the mVAI and MAGNIFI-CD, can be adapted and used for children. Further research to assess the operating properties of the indices when used in a pediatric patient population is ongoing.
Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A.
Laetsch, Theodore W. , Ludwig, Kathleen , Barkauskas, Donald A. , Voss, Stephan D. , DuBois, Steven G. , Ronan, Joan, Rudzinski, Erin R. , Memken, Amanda , Robinson, Krystal, Sorger, Joel, Bhatla, Teena, Church, Alanna J. , Fox, Elizabeth , Weigel, Brenda J. , Hall, David , Reid, Joel M. , Crompton, Brian D.

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 10008-10008

10.1200/jco.2023.41.16_suppl.10008 Get It

10008 Background: NTRK1/2/3 gene fusions (TRK fusions) occur in a range of pediatric cancers and are the canonical molecular alterations in IFS. Larotrectinib is a highly selective TRK inhibitor that is FDA-approved for TRK fusion solid tumors in patients with no satisfactory alternative treatments or whose cancer has progressed following initial treatment. ADVL1823 (NCT03834961) evaluated larotrectinib in children with newly diagnosed TRK fusion positive solid tumors in two histology-based cohorts. Cohort A enrolled patients with IFS and is the focus of this analysis. Methods: Newly diagnosed patients ≤30 years old with unresectable or metastatic IFS and a locally identified NTRK gene fusion were eligible for Cohort A utilizing a Simon 2-stage design. Patients received larotrectinib at a dose of 100 mg/m2/dose BID (max of 100 mg/dose) continuously in 28-day cycles until disease progression, unacceptable toxicity, the tumor becoming surgically resectable following a minimum of 6 cycles of therapy, or completion of 12 cycles (for those with CR) or 26 cycles (for those with PR) of therapy. The primary endpoint was the centrally confirmed objective response rate within 6 cycles according to RECIST 1.1; response assessment occurred every 2 cycles for the first 6 cycles. The data cutoff was December 31, 2022. Results: Between October 2019 and May 2022, 18 patients with IFS were enrolled from 14 centers. The median age was 2 months (range <1 month to 4.6 years). NTRK fusions included presumed/confirmed ETV6: NTRK3, n=15, NTRK3 (partner unconfirmed), TMP3: NTRK1 and DCTN1: NTRK1, n=1 each, and were identified by FISH (n=8), NGS (n=7), and PCR (n=3). 17 of 18 patients (94%) demonstrated confirmed objective responses (16 PR and 1 CR,) resulting in closure to enrollment after meeting the pre-specified efficacy threshold. The only patient without confirmed response demonstrated 79% tumor reduction after cycle 2, but no confirmatory scan was obtained within the first 6 cycles. No patient discontinued therapy within the first 6 cycles due to disease progression or toxicity. Four (22%) patients had dose limiting toxicities: 2 neutropenia (both CTCAE V5 grade (G)4) and 1 each G3 AST increase and G3 weight loss. All patients resumed therapy following a dose reduction. Treatment-related grade ≥ 3 toxicities occurred in 7 patients, most commonly neutropenia (n=5, 3 G3, 2 G4). Conclusions: Larotrectinib is highly active and well tolerated in newly diagnosed patients with IFS. Enrollment of this very rare molecularly defined patient population was feasible within the COG. Ongoing follow-up will evaluate durability of response after treatment discontinuation at protocol specified response-adapted timepoints with or without surgical resection of tumor. Clinical trial information: NCT03834961 .
A phase 1/2 study of bay 18953444 (Elimusertib) in pediatric patients with relapsed or refractory solid tumors: Initial report of the phase 1 results of PEPN2112.
Liu, Xiaowei , Denic, Kristina Z., Militano, Olga, Church, Alanna J. , Voss, Stephan D. , Fox, Elizabeth , Weigel, Brenda J. , Ortiz, Michael V. , Bender, Julia Glade , Minard, Charles G. , Reid, Joel M. , Kentsis, Alex , Reynolds, C. Patrick

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: e15131-e15131

10.1200/jco.2023.41.16_suppl.e15131 Get It

e15131 Background: Elimusertib is a highly selective oral inhibitor of the Ataxia telangiectasia and Rad3 related (ATR) kinase, which is required for efficient end-joining repair of double-stranded breaks, particularly during DNA replication. Many pediatric cancers involve potential ATR susceptibilities such as increased replication stress due to oncogenic fusions, specific DNA damage repair (DDR) deficiencies, oncogenic activation of DNA damage and nucleases such as PGBD5, as well as alternative lengthening of telomeres. We report the initial phase 1 results of PEPN2112 (NCT05071209), an ongoing pediatric phase 1/2 clinical trial of elimusertib monotherapy. Methods: Eligible patients (pts) included children, adolescents, and young adults with relapsed or refractory tumors with: (1) Ewing sarcoma or related EWSR1 fusion positive tumors (EWS), (2) alveolar rhabdomyosarcoma, PAX3-FOXO1 fusion positive (aRMS), or (3) non-CNS primary tumors exhibiting specific DDR pathway defects anticipated to sensitize to ATR inhibition. For pts < 18 years (yrs), a rolling-six design was used to evaluate elimusertib administered BID x3 days/week of a 28-day cycle starting at the adult equivalent recommended phase 2 dose (RP2D) of 24 mg/m2/dose (max 40 mg) with a potential de-escalation to 18 mg/m2/dose (max 30 mg). The pediatric RP2D determination was based upon dose limiting toxicity (DLT) criteria (CTCAEv5) during cycle 1. Pharmacokinetic (PK) studies were performed. Pts > 18 yrs could enroll onto the phase 2 cohorts at the adult RP2D simultaneously with the pediatric phase 1. Once the pediatric RP2D was defined, pts < 18 yrs accrued to the phase 2 cohorts and a PK expansion for pts < 12 yrs was opened. Results: 8 eligible pts were enrolled (4 males) on the phase 1 part of the study. 2 pts were inevaluable for DLT as they received < 75% of protocol therapy. Median (range) age was 13 (10-17) yrs. Diagnoses included: EWS (n = 4) and 1 pt each with aRMS, adrenocortical carcinoma, clear cell sarcoma, and osteosarcoma. At 24 mg/m2/dose, no DLTs were observed. Toxicities were hematologic, with grade 3 toxicities including anemia (n = 3), neutropenia (n = 4), and decreased white blood cells (n = 1). One pt experienced grade 4 lymphopenia. There were no grade 3/4 non-hematologic toxicities. Day 1 mean ± SD values of Tmax, Cmax, AUC0-8h and t1/2 were 1.6 ± 0.5 h, 1532 ± 385 ng/mL, 5863 ± 1841 h*ng/mL and 3.6 ± 0.9 h, respectively. Conclusions: Elimusertib-related toxicities were primarily hematologic. The RP2D for elimusertib monotherapy in pediatric pts is 24 mg/m2/dose (max 40 mg) orally BID x3 days/week continuously, analogous to dosing in adults with similar PK. Phase 2 and PK expansion cohorts as well as pharmacodynamic studies are ongoing. Clinical trial information: NCT05071209 .
Importance of clinical decision making in precision oncology: Discordance in recommendation between next generation sequencing test vendor and molecular tumour board in India.
Davis, Sissmol , I, Anu R , Suryavanshi, Moushumi , Dawood, Shaheenah , Panda, Pankaj Kumar , Nag, Shona, Das, Arunangshu, Rohatgi, Nitesh, Shah, Riyaz , Thampy, Cherian, Mukherji, Deborah , Shilpakar, Ramila , Mullapally, Sujith Kumar, Mathew, Aju , Sirohi, Bhawna , Dawood, Shaheenah , Popat, Sanjay , Parikh, Aparna R. , Yadav, Siddhartha , Mehta, Prashant , Singh, Randeep K.

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: e15050-e15050

10.1200/jco.2023.41.16_suppl.e15050 Get It

e15050 Background: Molecular tumour boards (MTB) facilitate discussions among medical professionals, scientists, bioinformaticians and geneticists for clinical application of precision oncology, via interpretation of various genomic sequencing studies, most commonly Next Generation Sequencing (NGS). NGS test vendor recommendation may differ from the MTB recommendations. We aim to study the discordance rate between these recommendations. Methods: MTB discussions between April 1, 2021 and December 31, 2021, were retrospectively evaluated. MTBs which assessed NGS reports with or without significant genetic mutations but with drug recommendations were included. NGS testing was done with multiple vendors. Patients from all over India, Nepal, Bangladesh, Dubai and Abu Dhabi were discussed. We excluded MTBs which assessed NGS data without any drug recommendations. We compared therapeutic recommendations provided in the NGS report with the first-choice recommendation in the MTB discussion. Recommendation discordance was defined as disagreement between the NGS recommendation and the first MTB recommendation that either instructed its implementation either immediately or on disease progression. Results: 70 MTB data was studied. 49 MTBs assessing NGS reports of 49 unique patients (median age 54 years; range, 32-82) were included in the study. 13 patients had lung cancer, 10 colorectal, 6 breast, 7 hepatopancreatobiliary, 4 carcinoma of unknown primary and 9 others. 17 did not provide any treatment recommendations and hence were excluded. 4 were discussions based on NGS reports previously discussed in an MTB that was already included in the study, hence were excluded. Recommendation discordance rate was 49% (24 of 49). Conclusions: To our knowledge, this is the first study that assessed discordance rate in recommendations between NGS report and MTB from a low- and middle-income country setting. Accurate clinical translation of complex genomic data is at the forefront of personalized cancer care.